Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Neuroleptic

or Phenethylamine

or [[:Category:Antianginals|Antianginal]]

Use the filters below to narrow your results.

None (25) · Calan, Calan SR, Verelan, Verelan PM, Isoptin SR (1) · Cardizem, Tiazac, Cartia XT, Dilacor XR, Taztia XT, Matzim LA (1) · Fanapt (1) · Geodon (1) · Imdur (mononitrate ER), Isordil (dinitrate); generics; with hydralazine as BiDil for HFrEF in self-identified Black patients (1) · Inapsine (1) · Invega (1) · Latuda (1) · Loxitane (1) · Mellaril (1) · Moban (1) · Navane (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Nitrostat, Nitrolingual, NitroMist, Nitro-Bid, Nitro-Dur, Minitran, Rectiv (1) · Norvasc, Katerzia (1) · Orap (1) · Procardia, Procardia XL, Adalat CC, Afeditab CR (1) · Prolixin (1) · Saphris (1) · Stelazine (1) · Thorazine (1) · Trilafon (1)

None (4) · 5-HT2A agonist (12) · 5-HT2A agonist; long duration (1) · 5-HT2A agonist; MAO inhibitor (1) · 5-HT2A agonist; milder than other 2C-x (1) · 5-HT2A partial agonist (1) · Butyrophenone D2 antagonist (1) · D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) · D2/5-HT2A antagonist (1) · D2/5-HT2A antagonist; 5-HT7 antagonist (1) · D2/5-HT2A antagonist; active metabolite of risperidone (1) · D2/5-HT2A antagonist; SRI and NRI (1) · Dibenzoxazepine D2/5-HT2 antagonist (1) · Dihydroindolone D2 antagonist (1) · Diphenylbutylpiperidine D2 antagonist (1) · Extremely potent 5-HT2A agonist; vasoconstrictor (1) · Extremely potent 5-HT2A agonist; very long duration (1) · Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) · Phenothiazine D2 antagonist (4) · Potent 5-HT2A agonist (5) · Potent 5-HT2A agonist; no oral activity (1) · Potent 5-HT2A agonist; very long duration (1) · Thioxanthene D2 antagonist (1) · Very potent 5-HT2A agonist; long duration (1) · '"`UNIQ--vote-00000073-QINU`"' The long half-life gives smooth, once-daily BP control with low rebound. CYP3A4 substrate; pedal edema is the characteristic, dose-related, non-fluid-overload side effect'"`UNIQ--ref-00000074-QINU`"'. (1) · '"`UNIQ--vote-0000063C-QINU`"' Avoid in HFrEF (negative inotropy). CYP3A4 substrate AND moderate inhibitor — interacts substantially with statins (especially simvastatin), tacrolimus, cyclosporine, and many other CYP3A4 substrates'"`UNIQ--ref-0000063D-QINU`"'. (1)

None (41) · 2.5-5 mg PO once daily; titrate to 10 mg/d (1) · ER 180-240 mg PO once daily; IR 30 mg PO QID; IV 0.25 mg/kg over 2 min for acute rate control, then 5-15 mg/h infusion (1) · ER 30-60 mg PO once daily; immediate-release 10 mg PO TID (now rarely used for hypertension due to reflex tachycardia) (1) · IR 80-120 mg PO TID; ER 180-240 mg PO daily; IV 2.5-5 mg over 2 min for SVT termination (under monitoring); cluster prophylaxis up to 480-960 mg/d in divided doses (1) · Isosorbide mononitrate ER: 30-60 mg PO once daily in the morning, titrate to 120-240 mg/d; isosorbide dinitrate IR: 5-20 mg PO TID with a 12-14 hour nitrate-free interval to prevent tolerance (1) · SL 0.3-0.6 mg every 5 minutes up to 3 doses for acute angina (call EMS if not resolved after the third); IV infusion 5-10 mcg/min titrated; transdermal patch 0.2-0.4 mg/hr for 12-14 hours daily (nitrate-free interval prevents tolerance) (1)

None (41) · 10, 20 mg IR capsules; 30, 60, 90 mg ER tablets (1) · 2.5, 5, 10 mg tablets; 1 mg/mL oral suspension (1) · IR 30, 60, 90, 120 mg tablets; multiple ER capsules and tablets 60-420 mg; IV 5 mg/mL (1) · IR 40, 80, 120 mg tablets; SR/ER 100-360 mg; IV 2.5 mg/mL (1) · Mononitrate 10, 20 mg IR; 30, 60, 120 mg ER; dinitrate 5, 10, 20, 30, 40 mg IR and ER (1) · SL 0.3, 0.4, 0.6 mg tablets; lingual spray 0.4 mg/spray; ER 2.5-9 mg capsules; transdermal patch 0.1-0.8 mg/hr; 2% ointment; 0.4% rectal ointment; 5 mg/mL IV (1)

None (41) · 10 mg/d (1) · 120 mg/d (ER); IR not for chronic hypertension (1) · 240 mg/d (mononitrate ER); 160 mg/d (dinitrate) (1) · Indication-specific; titrated to effect (1) · ~480 mg/d (oral) for cardiovascular indications; higher off-label for cluster (1) · ~480 mg/d (oral); IV per protocol (1)

None (40) · insufflated (1) · IV (3) · lingual spray (1) · MI reports) (1) · multiple ER formulations) (1) · Oral (3) · Oral (IR (1) · Oral (IR and multiple ER) (1) · oral ER (1) · Oral; sublingual IR is discouraged (uncontrolled BP drops (1) · PR (1) · rectal (1) · Sublingual (1) · sublingual (dinitrate) (1) · topical (1) · transdermal (1)

None (40) · 45-75 min (oral) (1) · BP effect within 24 hours; full effect at 1-2 weeks (long half-life) (1) · IR 20 minutes; ER ~6 hours (1) · IV: 1-3 minutes (SVT termination); PO IR: 30-60 minutes; ER: hours (1) · IV: 3-7 minutes (rate control); PO IR: 30-60 minutes; ER: hours (1) · SL/spray: 1-3 minutes; IV: minutes; patch: 30-60 minutes (1) · SL: 2-5 minutes; PO mononitrate: 30-60 minutes (1)

None (40) · 24 hours (1) · 4-8 h (1) · IR 4-8 hours; ER 24 hours (1) · IR: 4-8 hours; ER: 24 hours (1) · IR: 6-8 hours; ER: 24 hours (1) · Mononitrate ER: 12-24 hours; dinitrate IR: 4-6 hours (1) · SL: 30 minutes; patch: 12-14 hours; IV continuous (1)

None (40) · 1-3 minutes (very short)'"`UNIQ--ref-00000C0F-QINU`"' (1) · 2-5 hours (IR); ER formulations extend functional duration via osmotic/matrix release'"`UNIQ--ref-0000074D-QINU`"' (1) · 3-4.5 hours (IR); 5-7 hours (ER; effective duration 24 hours via formulation)'"`UNIQ--ref-00000642-QINU`"' (1) · 3-7 hours (IR); functional 24 hours (ER)'"`UNIQ--ref-00000A6B-QINU`"' (1) · 30-50 hours'"`UNIQ--ref-00000078-QINU`"' (1) · Mononitrate ~5 hours; dinitrate ~1 hour'"`UNIQ--ref-00001461-QINU`"' (1) · Not well characterized (1)

None (40) · 64-90% (oral; not affected by food)'"`UNIQ--ref-00000079-QINU`"' (1) · Highly route-dependent: SL bypasses first-pass; oral has extensive first-pass (used only for chronic ER preparations); transdermal predictable'"`UNIQ--ref-00000C10-QINU`"' (1) · Mononitrate ~100% (no first-pass; the principal advantage over dinitrate); dinitrate ~20%'"`UNIQ--ref-00001462-QINU`"' (1) · Not well characterized (1) · ~20-35% (oral; extensive first-pass via CYP3A4 with R/S enantiomer differences)'"`UNIQ--ref-00000A6C-QINU`"' (1) · ~40% (oral; extensive first-pass via CYP3A4)'"`UNIQ--ref-00000643-QINU`"' (1) · ~50% IR (extensive first-pass via CYP3A4); ER products release-rate-limited'"`UNIQ--ref-0000074E-QINU`"' (1)

None (40) · Limited data.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Limited data; alternative antihypertensives generally preferred. Crosses placenta.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Limited data; case series and registries suggest no major teratogenicity but other antihypertensives (labetalol, nifedipine) are typically preferred.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Limited data; labetalol/nifedipine generally preferred. Crosses placenta.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Not established (1) · Oral nifedipine is one of the preferred agents for severe hypertension in pregnancy and for tocolysis in preterm labor.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Used in obstetric emergencies (uterine relaxation, severe hypertension) when needed; otherwise limited routine use.[[[Pharmacopedia:Citation needed|citation needed]]] (1)

None (40) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (6)

2

A

B

C

D

E

F

I

L

M

N

P

T

V

Z